These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10748238)

  • 1. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.
    Hohlbaum AM; Moe S; Marshak-Rothstein A
    J Exp Med; 2000 Apr; 191(7):1209-20. PubMed ID: 10748238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity.
    Shudo K; Kinoshita K; Imamura R; Fan H; Hasumoto K; Tanaka M; Nagata S; Suda T
    Eur J Immunol; 2001 Aug; 31(8):2504-11. PubMed ID: 11500835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors.
    Hohlbaum AM; Gregory MS; Ju ST; Marshak-Rothstein A
    J Immunol; 2001 Dec; 167(11):6217-24. PubMed ID: 11714783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers.
    Li XK; Fujino M; Sugioka A; Morita M; Okuyama T; Guo L; Funeshima N; Kimura H; Enosawa S; Amemiya H; Suzuki S
    Transplantation; 2001 Feb; 71(4):503-8. PubMed ID: 11258428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
    Hofmann A; Blau HM
    Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
    Zeytun A; Nagarkatti M; Nagarkatti PS
    Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils.
    Fecho K; Cohen PL
    J Leukoc Biol; 1998 Sep; 64(3):373-83. PubMed ID: 9738665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas Ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver.
    Lombard C; McKallip RJ; Hylemon PB; Nagarkatti PS; Nagarkatti M
    Clin Immunol; 2003 Nov; 109(2):144-53. PubMed ID: 14597213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
    Springer ML; Kraft PE; Blau HM
    Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants.
    Kang SM; Braat D; Schneider DB; O'Rourke RW; Lin Z; Ascher NL; Dichek DA; Baekkeskov S; Stock PG
    Transplantation; 2000 May; 69(9):1813-7. PubMed ID: 10830216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fas ligand is not a main mechanism used by tumors to counteract antitumor immunity.
    Chen CM; Song W; Kao JY; Zheng QD; Chen JJ
    Front Biosci; 2004 Jan; 9():448-56. PubMed ID: 14766381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of IL-17 in Fas ligand-induced inflammation.
    Umemura M; Kawabe T; Shudo K; Kidoya H; Fukui M; Asano M; Iwakura Y; Matsuzaki G; Imamura R; Suda T
    Int Immunol; 2004 Aug; 16(8):1099-108. PubMed ID: 15237105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
    Bonardelle D; Benihoud K; Kiger N; Bobé P
    J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A; Odorico JS
    Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.